Renata Libianto
Overview
Explore the profile of Renata Libianto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ooi A, Khan H, Akram M, Fuller P, Milat F, Yang J, et al.
J Clin Endocrinol Metab
. 2025 Mar;
PMID: 40052768
Context: Primary aldosteronism (PA) is the most common cause of endocrine hypertension. While elevated serum parathyroid hormone (PTH) levels have been associated with PA, the extent and nature of this...
2.
Yang J, Burrello J, Goi J, Reincke M, Adolf C, Asbach E, et al.
Lancet Diabetes Endocrinol
. 2025 Jan;
13(2):119-133.
PMID: 39824204
Background: Primary aldosteronism can be treated medically but there is no standardised method to evaluate treatment outcomes. We aimed to develop criteria for assessing the outcomes of targeted medical treatment...
3.
Shah S, Libianto R, Gwini S, Russell G, Young M, Fuller P, et al.
J Endocr Soc
. 2024 Sep;
8(10):bvae148.
PMID: 39281005
No abstract available.
4.
Shah S, Libianto R, Gwini S, Rusell G, Young M, Fuller P, et al.
J Endocr Soc
. 2024 Jul;
8(8):bvae113.
PMID: 38957654
Introduction: Low-renin hypertension is an underrecognized subtype of hypertension with specific treatment options. This study aims to identify the prevalence in primary care and to compare patient characteristics to those...
5.
Tsan K, Yang J, Nainani A, Libianto R, Russell G
Fam Pract
. 2024 Jun;
41(5):851-856.
PMID: 38912620
Background: Primary aldosteronism (PA) is the most common treatable and potentially curable cause of secondary hypertension. Prompt diagnosis and management by primary care physicians (PCPs) is important given the increased...
6.
Yang J, McCarthy J, Shah S, Ng E, Shen J, Libianto R, et al.
J Endocr Soc
. 2024 Jun;
8(7):bvae109.
PMID: 38887633
Primary aldosteronism, characterized by the dysregulated production of aldosterone from 1 or both adrenal glands, is the most common endocrine cause of hypertension. It confers a high risk of cardiovascular,...
7.
Libianto R, Stowasser M, Russell G, Fuller P, Yang J
Exp Clin Endocrinol Diabetes
. 2023 May;
131(7-08):402-408.
PMID: 37160153
Primary aldosteronism (PA), once considered a rare disease, is being increasingly recognized as an important cause of hypertension. It is associated with higher rates of cardiovascular complications compared to blood...
8.
Solanki P, Gwini S, Libianto R, Gabb G, Shen J, Young M, et al.
BMJ Open
. 2022 Nov;
12(11):e062406.
PMID: 36375972
Objectives: Primary aldosteronism (PA), the most common endocrine cause of hypertension, is associated with a higher risk of cardiovascular disease (CVD) than blood pressure (BP)-matched essential hypertension (EH). We aimed...
9.
Ng E, Gwini S, Libianto R, Choy K, Lu Z, Shen J, et al.
J Clin Endocrinol Metab
. 2022 Sep;
108(1):33-41.
PMID: 36179243
Context: The plasma aldosterone concentration (PAC), renin, and aldosterone-to-renin ratio (ARR) are used to screen for primary aldosteronism (PA). Substantial intra-individual variability of PAC and ARR using plasma renin activity...
10.
Zhang J, Yang J, Libianto R, Shen J, Fuller P, Grodski S, et al.
Surgery
. 2022 Sep;
172(6):1682-1688.
PMID: 36123178
Background: Primary aldosteronism is the most common surgically curable cause of endocrine hypertension. Management of the unilateral subtype of primary aldosteronism with adrenalectomy requires multidisciplinary input. It is unclear if...